Exclusive Summary

• Innovative First-in-Class Mechanism: As a pioneering bispecific antibody simultaneously targeting IL-6R and IL-23p19, it offers a novel synergistic mechanism by blocking two key inflammatory pathways, potentially surpassing the efficacy of single-target drugs.
• Targets Huge Unmet Medical Needs: Aimed at multi-billion dollar global markets such as IBD, RA, and Psoriasis, it is designed to treat patient populations who are non-responsive or have lost response to existing therapies.
• Strong Preclinical Data Support: Preclinical studies have confirmed its high affinity and potent biological activity against both IL-6R and IL-23p19 targets, providing a solid scientific foundation for potentially achieving deeper clinical remission.
• Clear Global Partnership Value: As a preclinical candidate with high differentiation and immense commercial potential, it is an ideal license-in asset for overseas pharmaceutical companies seeking a next-generation, blockbuster-potential immunology pipeline.

Asset Materials

Contact Us for Full Materials